期刊文献+

EZH2、p53蛋白表达与TNBC患者病理特征的关系 被引量:1

Relationship of EZH2 and p53 Expression with Pathological Characteristics of TNBC Patients
下载PDF
导出
摘要 目的探讨果蝇zeste基因增强子同源物2(EZH2)、p53肿瘤蛋白在三阴性乳腺癌(TNBC)肿瘤组织中的表达及其临床意义。方法选取我院收集的TNBC肿瘤标本120例(收集时间:2015年6月至2016年6月)作为TNBC组,同期收集的40例良性乳腺疾病切除组织(良性组),采用免疫组化染色检测各组标本中EZH2、p53蛋白,探讨二者表达水平与患者临床病理学特征的关系。结果 NBC组的EZH2蛋白、p53蛋白阳性表达水平分别为56.67%、50.83%,良性组分别为20.00%、17.50%,两组比较差异有统计学意义(P<0.05);TNBC组的EZH2蛋白阳性表达与患者的肿瘤直径、TNM分期有关(P<0.05);TNBC组的p53蛋白阳性表达与患者的组织学分级、淋巴结转移有关(P<0.05)。结论 TNBC肿瘤组织中的EZH2蛋白、p53蛋白阳性表达水平显著高于乳腺良性病变组织,并且与肿瘤的病理特征有一定的相关性。 Objective To investigate the expression and its clinical significance of enhancer of zeste homolog 2 (EZH2) and p53 in triple negative breast cancer(TNBC)tissue. Methods 120 specimens of TNBC acquired in our hospital between June 2015 and June 2016 were selected as TNBC group and 40 excisional specimens of benign breast disease acquired during the corresponding period were selected as benign group. EZH2 and p53 in each specimens of the two groups were detected by immunohistochemical staining and the relationship between their expression and clinicopathological characteristics of patients were investigated. Results The positive expression rates of EZH2 and p53 in TNBC group were 56. 67% and 50. 83% ,respectively,while those in benign group were 20.00% and 17. 50% ,the difference between the two groups being statistically significant(P 〈0. 05). Positive expression of EZH2 in TNBC group was related to diameter and TNM stage (P 〈 0. 05). Positive expression of p53 in TNBC group was related to histological grade and lymphatic metastasis ( P 〈 0. 05 ). Conclusion Positive expression rates of EZH2 and p53 in TNBC tissues are significantly higher than those in benign breast lesions, and have relationship with pathological characteristics of tumor.
出处 《四川医学》 CAS 2018年第2期144-148,共5页 Sichuan Medical Journal
关键词 EZH2蛋白 P53蛋白 三阴性乳腺癌 临床病理特征 EZH2 protein p53 protein triple negative breast cancer clinicopathological characteristics
  • 相关文献

参考文献4

二级参考文献33

  • 1Jemal A, Siegel R, Xu JQ, et al. Cancer statistics[J]. Cancer J Clin, 2010, 60(5): 277-300.
  • 2Min J, Zaslavsky A, Fedele G, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB[J]. Nat Med, 2010, 16(3): 286-294.
  • 3Moore HM, Gonzalez ME, Toy KA, et al. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis[J]. Breast Cancer Research and Treatment, 2013, 138(3): 741-752.
  • 4Chang CJ, Hung MC. The role of EZH2 in tumor progression[J]. Br J Cancer, 2012, 106(2): 243-247.
  • 5Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer[J]. Cancer Research, 2012, 72(12): 3091-3104.
  • 6Au SL, Wong CC, Lee JM, et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis[J]. Hepatology, 2012, 56(2): 622-631.
  • 7Crea F, Fornaro L, Bocci G, et al. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis[J]. Cancer Metastasis Reviews, 2012, 31(3-4): 753-761.
  • 8Xu L, Beckebaum S, Iacob S, et al. MicroRNA-101 inhibits human hepatocellular Carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity[J]. Journal of Hepatology, 2014, 60(3): 590-598.
  • 9Fluge , Gravdal K, Carlsen E, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis[J]. Br J Cancer, 2009, 101(8): 1282-1289.
  • 10Yon R. Linking JNK-STAT3-Akt signaling axis to EZH2 phosphorylation: A novel pathway of carcinogenesis[J]. Cell Cycle, 2013, 12(2): 202-203.

共引文献48

同被引文献11

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部